| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | ezetimibe/simvastatin (Inegy®) |
| Formulation | 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg tablet |
| Reference number | 143 |
| Indication | Adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia in patients not appropriately controlled with a statin alone or patients already on a statin and ezetimibe. Adjunctive therapy to diet for use in patients with homozygous familial hypercholesterolaemia |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 15/03/2005 |